AbbVie

News

Tenpoint eyes presbyopia drug launch after FDA nod

Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

AbbVie turbocharges its US investment promise to $100bn

AbbVie finally agrees a Most-Favoured Nation pricing deal with the US administration, with a $100 billion investment promise attached.

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

Tenpoint eyes presbyopia drug launch after FDA nod

CMS's Medicare price negotiations start round three

AbbVie turbocharges its US investment promise to $100bn

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

FDA starts priority review of BeOne's Venclexta rival

Approvals extend use of Roche, AbbVie drugs in lymphoma

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

AbbVie

Editor's Picks